Login to Your Account

Advicenne eyes 2018 filing for ADV-7103 in renal tubular acidosis

By Cormac Sheridan
Staff Writer

Monday, September 11, 2017

DUBLIN – Advicenne SA plans to seek European approval in the second half of next year for ADV-7103 for treating distal renal tubular acidosis on the back of data from an open-label phase III trial, in which the drug attained its primary endpoint, demonstrating its noninferiority vs. the standard of care.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription